Endothelial function in women of the Kronos Early Estrogen Prevention Study

Climacteric

Volumn 18, Issue 2, 2015, Pages 187-197

  Kling, J M ^a   Lahr, B A ^a   Bailey, K R ^a   Harman, S M ^b   Miller, V M ^a   Mulvagh, S L ^a  

^a MAYO CLINIC   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cardiovascular disease; carotid intima medial thickness; digital tonometry; endothelium; estrogen; menopausal symptoms

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; CONJUGATED ESTROGEN; ESTRADIOL; ESTRONE; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PROGESTERONE; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TRIACYLGLYCEROL;

ADULT; ARTERIAL WALL THICKNESS; ARTICLE; CARDIOVASCULAR PARAMETERS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY CALCIFICATION; DIET RESTRICTION; DRUG INTERMITTENT THERAPY; ENDOTHELIAL FUNCTION; ENDOTHELIUM; ESTRADIOL BLOOD LEVEL; ESTRONE BLOOD LEVEL; FEMALE; FOLLOW UP; GLUCOSE BLOOD LEVEL; HORMONAL THERAPY; HOT FLUSH; HUMAN; INSOMNIA; MENOPAUSAL HORMONE TREATMENT; MENOPAUSE; NIGHT SWEAT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REACTIVE HYPEREMIA INDEX; SWEAT; SYSTOLIC BLOOD PRESSURE; TESTOSTERONE BLOOD LEVEL; TONOMETRY; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE; CARDIOVASCULAR DISEASES; DRUG EFFECTS; ESTROGEN THERAPY; HYPEREMIA; INTRADERMAL DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PHYSIOLOGY; PROSPECTIVE STUDY; VASCULAR ENDOTHELIUM;

ADMINISTRATION, CUTANEOUS; ADMINISTRATION, ORAL; ADULT; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; ESTRADIOL; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; HYPEREMIA; MENOPAUSE; MIDDLE AGED; PLACEBOS; PROGESTERONE; PROSPECTIVE STUDIES;

EID: 84924726762     PISSN: 13697137     EISSN: 14730804     Source Type: Journal    
DOI: 10.3109/13697137.2014.986719     Document Type: Article

References (41)

1. Walsh J M, P ignone M. D rug treatment of hyperlipidemia in women. JAMA 2004; 291: 2243-52
2. Steingart RM, Packer M, Hamm P, et al. Sex differences in the management of coronary artery disease. Survival and Ventricular Enlargement Investigators. N Engl J Med 1991; 325: 226-30
3. Bairey Merz CN, Shaw LJ, Reis SE, et al. Insights From the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE) Study. Part II: Gender differences in presentation, diagnosis, and outcome with regard to gender-based pathophysiology of atherosclerosis and macrovascular and microvascular coronary disease. J Am Coll Cardiol 2006; 47: S21-9
4. Michos ED, N asir K, B raunstein J B, e t a l. F ramingham risk equation underestimates subclinical atherosclerosis risk in asymptomatic women. Atherosclerosis 2006; 184: 201-6
5. Lakoski SG, Greenland P, Wong ND, et al. Coronary artery calcium scores and risk for cardiovascular events in women classifi ed as "low risk" based on Framingham Risk Score: The Multi-Ethnic Study of Atherosclerosis (MESA). Arch Intern Med 2007; 167: 2437-42
6. Tousoulis D, A ntoniades C, S tefanadis C. E valuating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005; 91: 553-8
7. Hamburg NM, Keyes MJ, Larson MG, et al. Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study. Circulation 2008; 117: 2467-74
8. Bonetti PO, P umper GM, Higano ST, Holmes DR Jr, Kuvin JT, Lerman A. Noninvasive identifi cation of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol 2004; 44: 2137-41
9. Celermajer DS, Sorensen KE, Bull C, Robinson J, Deanfi eld JE. Endothelium-dependent dilation in the systemic arteries of asymptomatic subjects relates to coronary risk factors and their interaction. J Am Coll Cardiol 1994; 24: 1468-74
10. Celermajer DS. Reliable endothelial function testing: at our fi ngertips? Circulation 2008; 117: 2428-30
11. Lieberman E H, G erhard M D, U ehata A, e t a l. F low-induced vasodilation of the human brachial artery is impaired in patients - 40 years of age with coronary artery disease. Am J Cardiol 1996; 78: 1210-14
12. Matsuzawa Y, Sugiyama S, Sugamura K, et al. Digital assessment of endothelial function and ischemic heart disease in women. J Am Coll Cardiol 2010; 55: 1688-96
13. Hamburg N, Charbonneau F, Gerhard-Herman M, Ganz P, Creager MA. Comparison of endothelial function in young men and women with a family history of premature coronary artery disease. Am J Cardiol 2004; 94: 783-5
14. Moreau K L, H ildreth K L, M editz A L, D eane K D, K ohrt WM. Endothelial function is impaired across the stages of the menopause transition in healthy women. J Clin Endocrinol Metab 2012; 97: 4692-700
15. Stampfer M J, C olditz G A. E strogen replacement therapy and coronary heart disease: a quantitative assessment of the epidemiologic evidence. Prev Med 1991; 20: 47-63
16. Bush TL, Cowan LD, Barrett-Connor E, et al. Estrogen use and all-cause mortality. Preliminary results from the Lipid Research Clinics Program Follow-Up Study. JAMA 1983; 249: 903-6
17. Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: Results from the Lipid Research Clinics Program Follow-up Study. Circulation 1987; 75: 1102-9
18. Wolf PH, Madans JH, Finucane FF, Higgins M, Kleinman JC. Reduction of cardiovascular disease-related mortality among postmenopausal women who use hormones: evidence from a national cohort. Am J Obstet Gynecol 1991; 164: 489-94
19. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. Ann Intern Med 2000; 133: 933-41
20. Ettinger B, F riedman G D, B ush T, Q uesenberry C P J r. Reduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol 1996; 87: 6-12
21. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefi ts of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33
22. Miller VM, Black DM, Brinton EA, et al. Using basic science to design a clinical trial: baseline characteristics of women enrolled in the Kronos Early Estrogen Prevention Study (KEEPS). J Cardiovasc Transl Res 2009; 2: 228-39
23. Clarkson TB, Appt SE. Controversies about HRT-lessons from monkey models. Maturitas 2005; 51: 64-74
24. Vita J, K eaney J F J r. H ormone replacement therapy and endothelial function. Arterioscler Thromb Vac Biol 2001; 21: 1867-9
25. Miller VM, Mulvagh SL. Sex steroids and endothelial function: translating basic science to clinical practice. Trends Pharmacol Sci 2007; 28: 263-70
26. Holm P, A ndersen H L, A ndersen M R, E rhardtsen E, S tender S. The direct antiatherogenic effect of estrogen is present, absent, or reversed, depending on the state of the arterial endothelium: A time course study in cholesterol-clamped rabbits. Circulation 1999; 100: 1727-33
27. Schierbeck L, Rejnmark L, Tofteng C, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomized trial. BMJ 2012; 345: e6409
28. The 2012 Hormone Therapy Position Statement of The North American Menopause Society. Menopause 2012; 19: 257-71
29. Mosca L, Benjamin EJ, Berra K, e t al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the American Heart Association. Circulation 2011; 123: 1243-62
30. de Villiers T J, G ass M L, H aines C J, e t a l. G lobal Consensus Statement on menopausal hormone therapy. Climacteric 2013; 16: 201-4
31. Mulvagh SL, Behrenbeck T, Lahr BA, et al. Endothelial function and cardiovascular risk stratifi cation in menopausal women. Climacteric 2010; 13: 45-54
32. Harman S M, B rinton E A, C edars M, et a l. K EEPS: The Kronos Early Estrogen Prevention Study. Climacteric 2005; 8: 3-12
33. Farr JN, Khosla S, Miyabara Y, Miller VM, Kearns AE. Effects of estrogen with micronized progesterone on cortical and trabecular bone mass and microstructure in recently postmenopausal women. J Clin Endocrinol Metab 2013; 98: E249-57
34. G erhard MD, Tawakol A, Haley EA, et al. Long-term estradiol therapy with or without progesterone improves endotheliumdependent vasodilation in postmenopausal women. Circulation 1996; 94: I-279
35. Best P JM, Berger P B, Miller V M, Lerman A. The effect of estrogen replacement therapy on plasma nitric oxide and endothelin-1 levels in postmenopausal women. Ann Intern Med 1998; 128: 285-8
36. Sorensen K E, D orup I, H ermann A P, M osekilde L. C ombined hormone replacement therapy does not protect women against the age-related decline in endothelium-dependent vasomotor function. Circulation 1998; 97: 1234-8
37. Harman SM, Black DM, Naftolin F, et al. Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: A randomized trial. Ann Intern Med 2014; 161: 249-60
38. O'Rourke S, Vanhoutte PM, Miller VM. Vascular pharmacology. In Creager MA, Dzau V, Loscalzo J, eds. Vascular Medicine, A Companion to Braunwald's Heart Disease. Philadelphia: Elsevier, 2006: 71-100
39. Onkelinx S, Cornelissen V, Goetschalckx K, Thomaes T, Verhamme P, Vanhees L. Reproducibility of different methods to measure the endothelial function. Vasc Med 2012; 17: 79-84
40. Kuvin JT, Mammen A, Mooney P, Alsheikh-Ali AA, Karas RH. Assessment of peripheral vascular endothelial function in the ambulatory setting. Vasc Med 2007; 12: 13-16
41. Heffernan K S, K aras R H, M ooney P J, P atel A R, K uvin J T. P ulse wave amplitude is associated with brachial artery diameter: implications for gender differences in microvascular function. Vasc Med 2010; 15: 39-45